Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CING vs CDIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CING Captures Overall Composite Edge (44.8 HOLD vs 39.4 SELL), While CDIO Leads 3–1 on Growth & Valuation Pillars

CING Overall Winner 6-Pillar Tally: CING 1 – 3 CDIO (2 Tie) Matrix Metrics: CING 4 – 3 CDIO

As of Nov 17, 2026, Cingulate Inc. (CING) captures the overall head-to-head institutional edge over Cardio Diagnostics Holdings Inc. (CDIO) on higher Unified Composite conviction (44.8/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–3 (led by Options & Positioning), while CDIO wins 3–1 across the 6-pillar growth and valuation breakdown. CING trades at $4.76 (N/M Forward P/E, 0.0% operating margin) versus CDIO at $1.75 (N/M Forward P/E, -42649.8% operating margin).

  • Growth vs. Quality Trade-Off: CING earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. CDIO 39.4/100 SELL) and 1.13β · 117% Vol risk profile, whereas CDIO leads top-line expansion (+25.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile CDIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CING vs CDIO
CING NASDAQ Head-to-Head Winner
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.8 · SMA20: $4.71 · SMA50: $4.82
CDIO NASDAQ
Cardio Diagnostics Holdings Inc. Common stock
In Vitro & In Vivo Diagnostic Substances
$1.75
-2.23% 1D
Market Cap $5.6M
TTM Revenue $15,185
Forward P/E N/M
Beta / 30D Vol 1.44β · 56% Vol
Unified Composite Score
39.4 / 100 SELL
Tech 20.0 Fund 35.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 45.8 · SMA20: $1.74 · SMA50: $1.84

6-Pillar Scorecard Institutional Category Breakdown (CING 1 – 3 CDIO)

Columns: Metric · CING · CDIO
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale CDIO
Revenue Growth (YoY) +0.0% +25.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $15,185
Market Cap $62.5M $5.6M
3. Profitability & Quality CDIO
Gross Margin N/A 100.0%
Operating Margin 0.0% -42649.8%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -198.7% -93.5%
4. Balance Sheet & Cash Flow CDIO
Cash Generation (TTM) -$21M -$6.3M
Cash Flow Margin N/A N/A
Net Cash / Leverage $22M Net Cash $6.5M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CING
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 111.1% (16th %ile) N/A (N/A)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CING (4) vs CDIO (3)
Institutional Metric CING CDIO Criterion Row Edge
Market Capitalization
Scale
$62.5M $5.6M Larger Scale CING
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +25.7% Higher Growth CDIO
Operating Margin (TTM)
Profitability
0.0% -42649.8% Higher Margin CING
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-198.7% -93.5% Higher ROE CDIO
52-Week Range Position
Momentum
18% ($3–$12) 11% ($1–$8) Stronger Trend CING
Beta / 30D Volatility
Risk Regime
1.13β · 117% Vol 1.44β · 56% Vol Lower Realized Risk CDIO
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 39.4 / 100 (SELL) Higher Composite CING
Trailing 12M Revenue (USD)
Operating Scale
N/A $15,185 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($22M Net Cash) -$6.3M ($6.5M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CING +2.46 pp
CING: +9.17% · CDIO: +6.71%
3M Horizon CING +2.38 pp
CING: -9.68% · CDIO: -12.06%
6M Horizon CDIO +19.31 pp
CING: +8.43% · CDIO: +27.74%
1Y Horizon CING +85.07 pp
CING: +36.39% · CDIO: -48.68%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs CDIO. Trailing 12-month operating profitability (CING 0.0% vs CDIO -42649.8%) and valuation multiples (CING N/M vs CDIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M
CDIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$15,185
Gross Margin100.0%
Op. Margin-42649.8%
ROE / Fwd P/E-93.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CDIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CDIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CDIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $5.6M market capitalization and -42649.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CING vs CDIO Key Questions & Quantitative Answers

As of Nov 17, 2026, Cingulate Inc. (CING) captures the overall head-to-head institutional edge over Cardio Diagnostics Holdings Inc. (CDIO) on higher Unified Composite conviction (44.8/100 HOLD vs. 39.4/100 SELL) after splitting the core matrix 4–3 (led by Options & Positioning), while CDIO wins 3–1 across the 6-pillar growth and valuation breakdown. CING trades at $4.76 (N/M Forward P/E, 0.0% operating margin) versus CDIO at $1.75 (N/M Forward P/E, -42649.8% operating margin). Growth vs. Quality Trade-Off: CING earns the overall head-to-head edge with a stronger Unified Composite Score (44.8/100 HOLD vs. CDIO 39.4/100 SELL) and 1.13β · 117% Vol risk profile, whereas CDIO leads top-line expansion (+25.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile CDIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CDIO leads the Growth & Scale pillar: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CDIO at +25.7% YoY revenue growth and +0.0% YoY earnings growth on $15,185 TTM revenue (100.0% gross margin, -42649.8% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $15,185 for CDIO. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CDIO.

CING and CDIO trade at balanced relative valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CDIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus CDIO (-93.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, CDIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.44β · 56% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.